PCOS is now PMOS: what the new name means for your health

26 Oct

If you were diagnosed with polycystic ovary syndrome (PCOS), you may have noticed a new set of letters appearing in the news this year. In May 2026, after a 14-year international process, the condition was officially renamed polyendocrine metabolic ovarian syndrome, or PMOS.

It would be easy to dismiss this as a bit of medical tidying up, but I don't think it is. The old name shaped how the condition was diagnosed, how it was explained to women and what care they were offered, often not for the better. The new name describes what many of us working in this field have seen in clinic for years: A whole-body hormonal and metabolic condition that happens to affect the ovaries, rather than an ovarian problem that happens to affect the rest of the body.

In this article I'll explain what has changed and why, what it means in practical terms if you are living with PMOS, and where nutrition fits in.

What is PMOS, and what has actually changed?

PMOS is the same condition that was previously called PCOS. It affects around one in eight women, an estimated 170 million worldwide, which makes it one of the most common hormonal conditions there is [1]. Only the name has changed: the condition itself, and the way it is diagnosed, remain the same.

The new name was agreed through what the researchers describe as the largest effort ever made to rename a medical condition. It was led by Professor Helena Teede at Monash University in Australia, working with the International Androgen Excess and PCOS Society and Verity, the UK charity for people with the condition. Fifty-six academic, clinical and patient organisations were involved, and more than 14,000 people living with the condition and health professionals from every world region contributed through surveys and workshops. The result was published in The Lancet on 12 May 2026 and announced at the European Congress of Endocrinology in Prague.

Each part of the new name was chosen deliberately:

Polyendocrine means that several hormone systems are involved, including androgens (such as testosterone), insulin, and the signalling between the brain and the ovaries.
Metabolic recognises the central role of insulin resistance and the condition's effects on long-term heart and metabolic health.
Ovarian keeps the link to the ovaries, because irregular ovulation, irregular periods and fertility concerns remain defining features for many women.
Syndrome reflects that this is a cluster of features that can look quite different from one woman to the next, rather than a single disease with a single cause.

There is a three-year transition period, and the new name will be fully built into the next international guideline in 2028. In the meantime you are likely to see both names, or "PMOS (formerly PCOS)", in GP letters, on health websites and in research.

Why the old name never really fitted

The "cysts" were never cysts

The word "polycystic" suggests the ovaries are full of cysts. They're not. What shows up on a scan are follicles: Small, fluid-filled sacs, each containing an egg, that have paused part way through their development because ovulation isn't happening regularly. Women with the condition do not have an increased rate of true, abnormal ovarian cysts [1]. Over the years I have met many women who were understandably frightened by the word, or who assumed their ovaries were somehow damaged. Neither is the case.

You don't need polycystic-looking ovaries to have it

Diagnosis has long relied on finding two out of three features: Irregular or absent ovulation, signs of higher androgens (such as excess facial or body hair, acne or thinning scalp hair, or raised levels on a blood test), and polycystic-appearing ovaries on a scan or, in adults, a raised level of a hormone called AMH. That means plenty of women have the condition without ever having polycystic-looking ovaries. Meanwhile many women who don't have the condition do have that appearance on a scan, particularly in their teens and early twenties, which is why scans are no longer recommended for diagnosis in adolescents [3].

In practice, the name led to some women being told "you can't have PCOS, your scan was clear", and others being diagnosed on the strength of a scan alone.

It made the condition sound like a fertility problem

Because the name pointed at the ovaries, the conversation often stopped at periods and pregnancy. A common experience was being told it would only really matter if and when you wanted to conceive. The metabolic side, which affects health for life, was frequently overlooked, and women found themselves passed between gynaecology, dermatology and their GP without anyone joining the dots.

The consequences are well documented. In the largest international survey of diagnosis experiences, a third of women waited more than two years for a diagnosis and nearly half saw three or more health professionals before getting one; most were dissatisfied with the information they were given [2]. It has been estimated that up to 70% of women with the condition remain undiagnosed [7]. The international consensus concluded that the old name contributed directly to delayed diagnosis, fragmented care and stigma.

A hormonal and metabolic condition at its core

The most important word in the new name, in my view, is "metabolic". Insulin resistance is reported in up to 85% of women with PMOS, and in around three-quarters of those in a healthy weight range [5]. This is not a condition that only affects women in larger bodies, and it never was.

Insulin and androgens are closely intertwined. Higher insulin levels can encourage the ovaries to produce more androgens, and higher androgens in turn influence where the body stores fat and how sensitive it stays to insulin. The two can feed each other in a loop, which helps explain why symptoms such as irregular cycles, acne, hair changes and difficulty managing weight so often travel together. I've explored this loop in more detail in a separate article, linked at the end of this one.

Because of this metabolic dimension, PMOS is associated with a higher lifetime risk of [3, 8]:

Type 2 diabetes, and diabetes in pregnancy (gestational diabetes)
Raised blood pressure and changes in cholesterol
Fatty liver disease (now called metabolic dysfunction-associated steatotic liver disease, or MASLD)
Cardiovascular disease, including in women who are not overweight
Changes to the womb lining when periods are very infrequent
Sleep apnoea
Anxiety, depression and disordered eating

That list can feel daunting, so it is worth saying clearly that these are increased risks, not certainties, and many of them are strongly influenced by things within your control. This is also a lifelong condition rather than one that belongs only to your reproductive years, so the metabolic side continues to matter through perimenopause and beyond. The point of naming it accurately is that it can be recognised early and looked after properly.

What the new name means for you

Your diagnosis still stands

If you were diagnosed with PCOS, you now have PMOS. Nothing needs to be retested or rediagnosed, and any treatment you are on continues as before. For many women the new name is simply a more accurate description of what they have been living with all along.

It's worth asking for the whole picture

The international guideline already recommends that women with the condition have their metabolic health checked regularly, including blood sugar, blood pressure and cholesterol, and that mood and emotional wellbeing are asked about too [3]. If you were diagnosed some years ago and the conversation has only ever been about periods or fertility, the new name is a good prompt to ask your GP whether these checks are up to date. Normal fasting glucose alone doesn't rule out insulin resistance, as blood sugar is often one of the last things to change.

Where nutrition fits in

The guideline is clear that a healthy lifestyle benefits everyone with PMOS, whatever their weight, and that no single diet has been shown to be better than others [3, 6]. I find that genuinely reassuring, because it means there is no perfect plan you are failing to follow. What matters is supporting the metabolic environment consistently over time.

In clinic, that usually means focusing on a handful of principles:

Regular, balanced meals built around protein, fibre-rich foods and healthy fats, which help keep blood sugar and insulin steadier through the day
Eating enough, because heavy restriction tends to backfire, both metabolically and emotionally
Building and keeping muscle, with resistance training in particular, as muscle is one of the body's most important tools for using glucose well
Sleep and stress, which both have a direct effect on insulin sensitivity and appetite
The emotional side of eating, which deserves real attention given how common disordered eating is in women with PMOS

None of this is about chasing a number on the scales. Metabolic health can improve meaningfully whether or not weight changes, and that is what matters most for long-term health.

It isn't your fault

Many women with PMOS have spent years being told, in one way or another, that their symptoms come down to willpower. The new name makes it plain that this is a hormonal and metabolic condition. Your body is responding to a particular set of signals, and those signals can be understood and worked with.

A name that finally fits

A new name won't change anyone's experience overnight, and it will take time for it to filter through to every GP surgery and clinic. But names shape conversations, and this one starts the conversation in the right place - with hormones and metabolism, the whole body and the whole of a woman's life. For the many women who were dismissed, misdiagnosed or told it only mattered for fertility, that recognition is long overdue.

If you take one thing away from this article, I'd like it to be this: PMOS is a manageable hormonal and metabolic condition, and understanding it properly is the first step towards looking after it well.

Read more

If you'd like to understand the link between insulin, androgens and where the body stores fat, and why "just lose weight" so often misses the point, you might find my earlier article helpful: PMOS and Weight: Why Where You Carry It Matters More Than the Number.

Want support with your own picture?

If you have PMOS and would like help understanding what is going on in your own body, and a realistic plan for supporting it, my Hormone Insights & Support Service is designed for exactly that. You can also book a session with me here.

And if you'd like more articles like this one, grounded in the science without the overwhelm, my free newsletter goes out every fortnight.

For practitioners and students

A few points from the 2023 International Evidence-based Guideline worth keeping front of mind as the terminology shifts [3]:

Diagnosis in adults uses the revised Rotterdam criteria (two of three: ovulatory dysfunction, clinical or biochemical hyperandrogenism, polycystic ovarian morphology). AMH may now be used as an alternative to ultrasound for morphology in adults, but not both together, to avoid overdiagnosis. Where ovulatory dysfunction and hyperandrogenism are both present, neither ultrasound nor AMH is needed.
Adolescents (within eight years of menarche) need both hyperandrogenism and ovulatory dysfunction; ultrasound and AMH are not recommended because of overlap with normal reproductive physiology.
Other causes of the presenting features (for example thyroid disease, raised prolactin, non-classic congenital adrenal hyperplasia) should be excluded medically.
Metabolic screening of glycaemic status, blood pressure and lipids is recommended regardless of BMI, alongside screening for depression, anxiety and disordered eating. Routine measurement of insulin resistance is not recommended in clinical practice, so interpret fasting insulin or HOMA-IR results with care if clients bring them.
Lifestyle advice should be individualised and weight-neutral in framing; no specific dietary composition has been shown to be superior. The guideline considers inositol experimental, with limited evidence, so discuss it as such.

In clinic, the most useful shift the new name invites is to assess every client with PMOS through a metabolic lens, whatever their size or main presenting concern, and to work alongside their GP so that recommended screening is actually happening.

References and further reading